Showing results (71-80 of 89) with videos related to

Sort By:
Pageof 9
Molecular Therapy. Methods & Clinical Development|March 24, 2020
Optimized Assessment of qPCR-Based Vector Copy Numbers as a Safety Parameter for GMP-Grade CAR T Cells and Monitoring of Frequency in PatientsAlexander Kunz, Ulrike Gern, Anita Schmitt, et al.
Methods in Molecular Biology (Clifton, N.J.)|October 18, 2022
Analysis of HDACi-Coupled Nanoparticles: Opportunities and ChallengesMarie Kühne, Susanne Hofmann, Henry Lindemann, et al.
Cerebrovascular Diseases (Basel, Switzerland)|March 28, 2021
Stroke Angel: Effect of Telemedical Prenotification on In-Hospital Delays and Systemic Thrombolysis in Acute Stroke PatientsPatrick Andreas Eder, Gunter Laux, Asarnusch Rashid, et al.
The Journal of Experimental Medicine|January 14, 2009
Adjuvanticity of a synthetic cord factor analogue for subunit Mycobacterium tuberculosis vaccination requires FcRgamma-Syk-Card9-dependent innate immune activationKerstin Werninghaus, Anna Babiak, Olaf Gross, et al.
Leukemia Research|June 11, 2013
A phase I dose-escalation study of MSC1992371A, an oral inhibitor of aurora and other kinases, in advanced hematologic malignanciesCarlos Graux, Anne Sonet, Johan Maertens, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 4, 2018
Prognostic value of [18F]FDG-PET/CT in multiple myeloma patients before and after allogeneic hematopoietic cell transplantationAntje Stolzenburg, Katharina Lückerath, Samuel Samnick, et al.
Transfusion|December 8, 2010
Adoptive transfer and selective reconstitution of streptamer-selected cytomegalovirus-specific CD8+ T cells leads to virus clearance in patients after allogeneic peripheral blood stem cell transplantationAnita Schmitt, Torsten Tonn, Dirk H Busch, et al.
Blood|November 6, 2007
RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responsesMichael Schmitt, Anita Schmitt, Markus T Rojewski, et al.
Frontiers in Immunology|January 30, 2018
Differences in Expansion Potential of Naive Chimeric Antigen Receptor T Cells from Healthy Donors and Untreated Chronic Lymphocytic Leukemia PatientsJean-Marc Hoffmann, Maria-Luisa Schubert, Lei Wang, et al.
BMJ Open|May 22, 2019
Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocolMaria-Luisa Schubert, Anita Schmitt, Leopold Sellner, et al.
Pageof 9